WALTHAM, Mass., Sept. 18, 2017 /PRNewswire/ -- Alere Inc. (NYSE:
ALR) ("Alere"), today announced that it has submitted written
notice to the New York Stock Exchange (the "NYSE") of its intention
to voluntarily delist its Series B Convertible Perpetual Preferred
Stock, par value $0.001 per share
(the "Preferred Stock"), from the NYSE. The voluntary delisting is
subject to and conditioned upon the completion of its acquisition
by Abbott Laboratories, an Illinois corporation ("Abbott").
Abbott has informed Alere that it intends to consummate its
offer to purchase all outstanding shares of the Preferred Stock
(the "Offer") following the completion of the acquisition of
Alere and upon satisfaction of all other conditions to the
Offer, and thereafter to cancel all remaining shares of
Preferred Stock in exchange for the liquidation preference, plus
accrued but unpaid dividends, due on such shares of Preferred
Stock. Following the delisting from the NYSE, the Preferred Stock
will not be listed or registered on another national securities
exchange or for quotation in a quotation medium.
Cautionary Statement Regarding
Forward-Looking Statements
This
communication contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
Readers can identify these statements by forward-looking words such
as "may," "could," "should," "would," "intend," "will," "expect,"
"anticipate," "believe," "estimate," "continue" or similar words. A
number of important factors could cause actual results of Alere and
its subsidiaries to differ materially from those indicated by such
forward-looking statements. These factors include, but are not
limited to, the risk factors detailed in Part I, Item 1A, "Risk
Factors," of our Annual Report on Form 10-K for the fiscal year
ended December 31, 2016 (as filed
with the Securities and Exchange Commission on June 5, 2017) and other risk factors identified
herein or from time to time in our periodic filings with the SEC.
Readers should carefully review these risk factors, and should not
place undue reliance on our forward-looking statements. These
forward-looking statements are based on information, plans and
estimates at the date of this communication. We undertake no
obligation to update any forward-looking statements to reflect
changes in underlying assumptions or factors, new information,
future events or other changes.
About Alere
Alere believes that when diagnosing and monitoring health
conditions, Knowing now matters.™ Alere delivers
reliable and actionable information by providing rapid diagnostic
tests, enhancing clinical and economic healthcare outcomes
globally. Headquartered in Waltham,
Mass., Alere focuses on rapid diagnostics for
cardiometabolic disease, infectious disease and
toxicology. For more information on Alere, please visit
www.alere.com.
View original
content:http://www.prnewswire.com/news-releases/alere-announces-intent-to-voluntarily-delist-series-b-convertible-perpetual-preferred-stock-from-the-nyse-conditioned-upon-the-completion-of-its-acquisition-by-abbott-300521640.html
SOURCE Alere Inc.